查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1757888

子宫肌瘤治疗设备的全球市场

Uterine Fibroid Treatment Devices
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 276 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球子宫肌瘤治疗设备市场规模将达 81 亿美元

全球子宫肌瘤治疗设备市场规模预计在2024年为53亿美元，预计2030年将达到81亿美元，2024年至2030年的复合年增长率为7.4%。外科手术是本报告分析的细分市场之一，预计其复合年增长率为8.7%，到分析期结束时规模将达到53亿美元。消融细分市场在分析期间内的复合年增长率预计为5.1%。

美国市场规模估计为 14 亿美元，中国市场预计复合年增长率为 11.8%

美国子宫肌瘤治疗设备市场规模预计2024年达到14亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到17亿美元，在2024-2030年的分析期间内，复合年增长率为11.8%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为3.6%和7.2%。在欧洲，预计德国市场的复合年增长率为4.9%。

全球「子宫肌瘤治疗设备」市场—主要趋势与驱动因素摘要

为什么晚期子宫肌瘤治疗的需求越来越大？

子宫肌瘤是一种子宫良性肿瘤，其全球负担正在显着增加，影响到 50 岁左右的 70-80% 的女性，有症状的病例会导致大量出血、骨盆疼痛、不孕和其他併发症。这种日益增长的盛行率直接影响了对有效、微创治疗方法的需求，特别是对于寻求保宫手术的育龄妇女。虽然子宫切除术历来是治疗的主要方法，但患者越来越偏好保宫手术，如肌瘤摘除、子宫动脉栓塞术 (UAE)，以及微创手术，如腹腔镜和机器人辅助手术。子宫切除术的耻辱感和社会影响正在加剧这种转变，特别是在高度重视生育能力的文化中。此外，生活方式的改变、妊娠晚期和肥胖已被确定为风险增加因素，从而导致早期诊断和治疗。医疗保健产业对女性健康的关注度不断提高，加上由于宣传宣传活动加强而导致的筛检和诊断率激增，进一步推动了子宫肌瘤治疗设备市场的发展。

科技和创新如何重新定义治疗方法？

创新突破是子宫肌瘤治疗发展的核心，医疗设备製造商不断推出尖端设备，旨在改善临床疗效、缩短恢復期并减少手术併发症。高强度聚焦超音波(HIFU)、射频消融 (RFA) 和磁振造影导引聚焦超音波手术 (MRgFUS) 等治疗技术正在重新定义非侵入性或微创治疗方法。这些设备能够精准靶向子宫肌瘤，且不会伤害周围组织，从而为患者提供快速缓解、更少副作用和门诊病人便利的治疗体验。此外，腹腔镜电动粉碎器和先进的子宫镜器械也正在不断改进，以提高安全性，尤其是考虑到过去对组织种植的担忧。机器人手术系统虽然价格昂贵，但越来越多地被三级医院采用，以提高复杂子宫肌瘤切除术的准确性。这些技术进步不仅增强了医生的信心，也为基层医院和门诊诊所提供了治疗的可能性，使优质医疗服务的可近性更加民主化。

医疗保健系统和提供者正在采取哪些措施来扩大医疗服务覆盖范围？

政策措施、保险覆盖改革和临床指引的不断演变，共同影响子宫肌瘤治疗的可近性。在高所得国家，微创门诊治疗的普及性降低了治疗成本，也让治疗更方便。许多政府和私人医疗机构现已将子宫肌瘤治疗列为女性基本医疗保健的一部分，从而改善了诊断、转诊和津贴流程。同时，中低收入国家 (LMIC) 正在加大对行动诊断单元、妇科医生培训计画以及旨在意识提升的公共卫生宣传活动的投资。跨国非政府组织和全球卫生组织也透过资助医疗任务和向农村医院捐赠设备，为能力建设做出贡献。此外，医院正在整合多学科子宫肌瘤诊所，将妇科、放射科和疼痛管理相结合，提供整体护理，确保患者获得正确的实证治疗。向门诊治疗和当日出院通讯协定的转变也在优化医院资源并减轻病患负担。

是什么推动了子宫肌瘤治疗设备市场的快速成长？

子宫肌瘤治疗设备市场的成长受到多种因素的驱动，这些因素与技术进步、临床实践和患者偏好密切相关。非侵入性和微创设备的广泛使用极大地改变了传统开放性手术的治疗模式，越来越多的患者寻求早期康復和保留生育能力。经阴道超音波和核磁共振等影像技术的改进导致诊断病例的增加，也推动了手术数量的增长。随着对子宫肌瘤认识的提高，女性正在积极寻求早期疗育和子宫切除手术的替代方案。此外，由于基于设备的子宫肌瘤治疗具有操作效率高且成本效益比佳的特点，私人和公共医疗保健提供者正在加大对此类治疗的投资。门诊和流动手术中心的不断增长，尤其是在北美和亚太部分地区，正在扩大新型治疗设备的商业性潜力。医疗支出的增加、生育延迟等人口结构变化以及肥胖和荷尔蒙失调发病率的上升进一步推动了需求。这些因素共同为未来几年的持续市场扩张奠定了坚实而多面向的基础。

部分

科技（手术、消融）、治疗方式（侵入性、微创、非侵入性）

调查企业范例（共42家企业）

  • AbbVie Inc.
  • Boston Scientific Corporation
  • CONMED Corporation
  • CooperSurgical Inc.
  • Ethicon, Inc.
  • Gynesonics
  • Hologic, Inc.
  • INSIGHTEC Ltd.
  • Karl Storz SE & Co. KG
  • Lumenis Be Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • ObsEva SA
  • Olympus Corporation
  • Philips Healthcare
  • Profound Medical Corp.
  • Siemens Healthineers AG
  • Stryker Corporation

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP35957

Global Uterine Fibroid Treatment Devices Market to Reach US$8.1 Billion by 2030

The global market for Uterine Fibroid Treatment Devices estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Surgical, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Ablation segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.8% CAGR

The Uterine Fibroid Treatment Devices market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global "Uterine Fibroid Treatment Devices" Market - Key Trends & Drivers Summarized

Why Is There a Rising Demand for Advanced Uterine Fibroid Treatments?

The global burden of uterine fibroids-benign tumors of the uterus-has grown substantially, affecting up to 70-80% of women by the age of 50, with symptomatic cases leading to heavy bleeding, pelvic pain, infertility, and other complications. This rising incidence is directly influencing the demand for effective, less invasive treatment modalities, particularly in reproductive-age women who seek uterine-sparing procedures. Historically, hysterectomy was the dominant treatment; however, patient preference is increasingly shifting toward uterus-preserving alternatives such as myomectomy, uterine artery embolization (UAE), and minimally invasive surgeries like laparoscopic and robotic-assisted interventions. The stigma and social implications of undergoing hysterectomy-especially in cultures where fertility is highly valued-are reinforcing this transition. In addition, lifestyle changes, late pregnancies, and obesity have been identified as risk-enhancing factors, leading to earlier diagnosis and treatment. The healthcare industry’s increased focus on women’s health and a surge in screening and diagnostic rates, due in part to better awareness campaigns, are further propelling the market for uterine fibroid treatment devices.

How Are Technology and Innovation Redefining Treatment Modalities?

Innovative breakthroughs are at the heart of the evolution in uterine fibroid management, with medical device manufacturers introducing cutting-edge equipment designed to improve clinical outcomes, shorten recovery periods, and reduce surgical complications. Technologies such as high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and MRI-guided focused ultrasound surgery (MRgFUS) are redefining non-invasive or minimally invasive treatment approaches. These devices enable precise targeting of fibroids without damaging surrounding tissues, offering patients rapid relief with fewer side effects and outpatient-level convenience. Additionally, laparoscopic power morcellators and advanced hysteroscopic tools are being refined to improve safety, especially in light of past concerns around tissue dissemination. Robotic surgical systems, though expensive, are increasingly employed in tertiary care hospitals to improve accuracy in complex fibroid removal. These technological advancements are not only increasing physician confidence but are also expanding treatment availability to lower-tier hospitals and outpatient clinics, democratizing access to quality care.

What Are Healthcare Systems and Providers Doing to Expand Access?

Access to fibroid treatment is being shaped by a combination of policy efforts, insurance coverage reforms, and evolving clinical guidelines. In high-income countries, broader insurance inclusion of less invasive and outpatient procedures has helped bring down costs and improve uptake. Many governments and private providers are now classifying uterine fibroid treatments as part of essential women’s healthcare, leading to better diagnosis, referral, and subsidization processes. At the same time, low- and middle-income countries (LMICs) are catching up, with investments in mobile diagnostic units, training programs for gynecologic surgeons, and public health campaigns aimed at raising awareness. Multinational NGOs and global health organizations are also contributing to capacity building by funding medical missions and donating devices to rural hospitals. Furthermore, hospitals are integrating multidisciplinary fibroid clinics combining gynecology, radiology, and pain management to offer holistic care, ensuring that patients receive tailored, evidence-based treatment options. The shift toward outpatient care and same-day discharge protocols is also optimizing hospital resources and reducing patient burden.

What’s Driving the Escalating Growth in the Uterine Fibroid Treatment Devices Market?

The growth in the uterine fibroid treatment devices market is driven by several factors closely linked to technology evolution, clinical practices, and patient preferences. The widespread availability of non-invasive and minimally invasive devices is dramatically shifting treatment patterns away from traditional open surgery, attracting a larger volume of patients seeking faster recovery and fertility preservation. The expanding pool of diagnosed cases-due to improved imaging techniques like transvaginal ultrasound and MRI-is also increasing procedural volumes. Patient behavior is playing a pivotal role; as awareness about fibroids rises, women are actively seeking early intervention and alternatives to hysterectomy. Additionally, private and public healthcare providers are increasingly investing in device-based fibroid treatments due to their procedural efficiency and favorable cost-benefit ratios. The increasing presence of outpatient and ambulatory surgery centers, particularly in North America and parts of Asia-Pacific, is expanding the commercial viability of newer treatment devices. Rising healthcare spending, demographic shifts such as delayed childbirth, and higher incidences of obesity and hormonal disorders are further fueling demand. Together, these factors form a robust and multifaceted foundation for sustained market expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Surgical, Ablation); Mode of Treatment (Invasive, Minimally Invasive, Non-Invasive)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Boston Scientific Corporation
  • CONMED Corporation
  • CooperSurgical Inc.
  • Ethicon, Inc.
  • Gynesonics
  • Hologic, Inc.
  • INSIGHTEC Ltd.
  • Karl Storz SE & Co. KG
  • Lumenis Be Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • ObsEva SA
  • Olympus Corporation
  • Philips Healthcare
  • Profound Medical Corp.
  • Siemens Healthineers AG
  • Stryker Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Uterine Fibroid Treatment Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Uterine Fibroids Drives Demand for Minimally Invasive Treatment Devices
    • Patient Shift Toward Outpatient and Daycare Procedures Spurs Adoption of Non-Invasive Technologies
    • Innovation in MRI-Guided and Ultrasound-Based Devices Expands Addressable Patient Pool
    • Increasing Awareness Among Women Throws the Spotlight on Early Diagnosis and Treatment
    • Favorable Reimbursement Policies Strengthen Business Case for Advanced Device Adoption
    • Aging Population and Rising Obesity Rates Accelerate Demand for Fibroid Treatments
    • Integration of AI and Robotics in Surgical Devices Generates Clinical Efficiency Opportunities
    • Expansion of Women's Health Clinics in Emerging Markets Sustains Market Penetration
    • Preference for Uterus-Preserving Treatments Drives Demand for Focused Ultrasound Systems
    • Shorter Recovery Times and Lower Complication Risks Boost Adoption Across Age Groups
    • Lack of Access and Cultural Barriers in Rural Areas Pose Distribution and Awareness Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uterine Fibroid Treatment Devices Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Surgical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Minimally Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Non-Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • JAPAN
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • CHINA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • EUROPE
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • FRANCE
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • GERMANY
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • INDIA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
  • AFRICA
    • Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030

IV. COMPETITION